936221-33-9

936221-33-9 structure

Name: CG-200745
Chemical Name: 2-Octenediamide, N1-[3-(dimethylamino)propyl]-N8-hydroxy-2-[(1-naphthalenyloxy)methyl]-, (2E)
CAS Number: 936221-33-9
Molecular Formula: C₂₄H₃₃N₃O₄
Molecular Weight: 427.53700
Catalog: Signaling Pathways Apoptosis MDM-2/p53
Create Date: 2017-07-05 06:18:09
Modify Date: 2025-08-21 12:39:15
CG-200745 is a potent HDAC inhibitor, with IC50s of <3 μM for sensitive non-small cell lung cancer (NSCLC) cell lines. CG-200745 induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of proteins encoded by p53 target genes, MDM2 and p21 (Waf1/Cip1) in human prostate cancer cells[1]. CG-200745 attenuates phosphorylation of p38 MAPK in kidneys and it has a renoprotective effect by suppressing renal fibrosis and inflammation in a unilateral ureteral obstruction (UUO) mouse model[2].

Name	2-Octenediamide, N1-[3-(dimethylamino)propyl]-N8-hydroxy-2-[(1-naphthalenyloxy)methyl]-, (2E)
Synonyms	cg 200745

Description	CG-200745 is a potent HDAC inhibitor, with IC50s of <3 μM for sensitive non-small cell lung cancer (NSCLC) cell lines. CG-200745 induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of proteins encoded by p53 target genes, MDM2 and p21 (Waf1/Cip1) in human prostate cancer cells[1]. CG-200745 attenuates phosphorylation of p38 MAPK in kidneys and it has a renoprotective effect by suppressing renal fibrosis and inflammation in a unilateral ureteral obstruction (UUO) mouse model[2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Apoptosis >> MDM-2/p53 Signaling Pathways >> MAPK/ERK Pathway >> p38 MAPK Signaling Pathways >> Cell Cycle/DNA Damage >> HDAC Signaling Pathways >> Epigenetics >> HDAC
Target	HDAC p53 p38 MAP kinase
In Vitro	CG-200745 (0-10 μM; 48 hours) reduces the Calu6 cells proliferation to 40% of untreated cells[1]. CG-200745 (3 μM; 1-24 hours) significantly increases Calu6 cells proportion in G2/M phase (69%)[1]. CG-200745 (0-10 μM; 1-24 hours) treatment with low concentration significantly increases the acetylation of histone H3 and H4 in Calu6 cells at various sites in a time-dependent manner up to 24 hours after treatment[1]. Cell Proliferation Assay[1] Cell Line: Calu6 cells Concentration: 0-10 μM Incubation Time: 48 hours Result: Reduced the cell proliferation to 40% of untreated cells. Cell Cycle Analysis[1] Cell Line: Calu6 cells Concentration: 3 μM Incubation Time: 1, 8, 12, 24 hours Result: Increased significantly cell proportion in G2/M phase (69%). Western Blot Analysis[1] Cell Line: Calu6 cells Concentration: 0-10 μM Incubation Time: 1, 4, 8, 12, 24 hours Result: Increased the acetylation of histone H3 and H4 at various sites in a time-dependent manner.
In Vivo	CG-200745 (p.o.; 30 mg/kg/day; for 7 days) attenuates oxidative stress, inflammatory cytokines, and adhesion molecules in UUO kidneys[2]. Animal Model: Male 8-week-old C57BL/6 J mice weighing 20~22 g of unilateral ureteral obstruction (UUO)[2] Dosage: 30 mg/kg Administration: P.o.; daily; for 7 days Result: Attenuated oxidative stress, inflammatory cytokines and adhesion molecules in UUO kidneys.
References	[1]. Chun SM, et al. Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells. PLoS One. 2015 Mar 17;10(3):e0119379. [2]. Choi HS, et al. Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease. Sci Rep. 2018 Aug 1;8(1):11546.

Density	1.148±0.06 g/cm3 (20 °C, 760 mmHg)
Molecular Formula	C₂₄H₃₃N₃O₄
Molecular Weight	427.53700
Exact Mass	427.24700
PSA	90.90000
LogP	4.06050

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

936221-33-9	1370466-81-1
90149-95-4	87269-59-8
37360-75-1	77469-70-6
9042-11-9	37247-87-3
108381-22-2	130405-40-2
2098002-27-6	2098124-54-8
2098002-32-3	2092103-35-8
959492-03-6	2097981-38-7
947169-31-5	2098054-12-5
959504-33-7	2097981-43-4